Business Context and Reporting Period
This Form 8-K was filed by National Research Corporation (NRC Health) on April 3, 2025. The report addresses Item 5.02 regarding the appointment of certain officers and changes to compensatory arrangements. The filing details a strategic leadership transition with Trent Green scheduled to become Chief Executive Officer and a director effective June 1, 2025.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation adjustments.
Material Changes
Material changes involve the restructuring of executive compensation packages for the Chief Operating Officer (Helen L. Hrdy) and the Chief Corporate Development Officer (Andrew Monnich) to align with the new strategic plan under incoming CEO Trent Green. Key changes include:
- Stock Grant: Approval of a grant of 100,000 shares of common stock to Ms. Hrdy, issuable on April 7, 2025.
- Restrictions: Shares are subject to repurchase at $1.00 if terminated for cause or resigning without good reason prior to the third anniversary. Transferability is restricted until the third anniversary, after which only 50% may be transferred during employment.
- Cash Bonus: A cash bonus equal to 66 2/3% of the value of the stock grant (based on the closing price prior to the grant date).
- Severance Adjustment: In the event of termination without cause or resignation with good reason after the third anniversary, Ms. Hrdy is entitled to one year of continued base salary payments.
- Forfeitures: Ms. Hrdy's previous severance agreement, participation in the 2024 long-term cash incentive plan, and an unvested performance-based option for 100,000 shares granted in January 2024 were terminated and forfeited.
- Base Salary: Ms. Hrdy's annualized base salary remains at $400,000.
Compensation for current CEO Michael D. Hays remains unchanged.
Guidance, Outlook, and Risks
The filing indicates a shift in strategic planning associated with the appointment of Mr. Green. The Compensation and Talent Committee explicitly stated the desire to align executive compensation with shareholder interests through stock ownership. No specific financial guidance, risk factors, or contingencies regarding operations were disclosed in this report.
Investor Verification Checklist
- Verify the closing stock price on April 2, 2025, to calculate the exact value of the cash bonus and stock grant for Ms. Hrdy.
- Confirm the specific terms of the compensation package granted to Andrew Monnich, which mirrors Ms. Hrdy's but is not detailed in this text.
- Monitor the June 1, 2025, effective date for Trent Green's assumption of the CEO role.
- Review the impact of forfeiting the 100,000 unvested performance-based options on total executive equity compensation.